Is dipeptidyl peptidase-4 inhibitor monotherapy cost-effective compared to sulfonylurea monotherapy in people with type 2 diabetes and chronic kidney disease in Thailand?
DPP-4 inhibitor monotherapy is not considered cost-effective compared to sulfonylurea monotherapy for patients with T2DM and CKD in Thailand.
Compared to SFU, DPP-4 inhibitor monotherapy is not a cost-effective treatment for people with T2DM and CKD in Thailand.
Permsuwan et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: